【结 构 式】 |
【分子编号】37409 【品名】(1R,2S)-2-aminocyclohexylamine; (1R,2S)-1,2-cyclohexanediamine 【CA登记号】1121-22-8 |
【 分 子 式 】C6H14N2 【 分 子 量 】114.19064 【元素组成】C 63.11% H 12.36% N 24.53% |
与该中间体有关的原料药合成路线共 2 条
合成路线1
该中间体在本合成路线中的序号:(I)By condensation of trans-(-)-1,2-diaminocyclohexane (I) with platinum (II) sulfate (II).
【1】 Lynch, F.B.; Castaner, J.; Serradell, M.N.; Blancafort, P.; NEO-SHP. Drugs Fut 1981, 6, 2, 96. |
【2】 Speer, R.J.; et al.; Antitumor activity of platinum complexes of 1,2-diaminocyclohexane isomers. J Clin Hematol Oncol 1978, 8, 2, 44-50. |
【3】 Kidani, Y.; et al.; Antitumor activity of water-soluble platinum (II) complexes of 1,2-cyclohexanediamine isomers. Gann 1978, 69, 5, 263-265. |
合成路线2
该中间体在本合成路线中的序号:(V)Condensation of 2,6-dichloropurine (I) with 3-chloroaniline (II) in hot pentanol yielded the 6-anilino purine (III). This was then alkylated at the N-9 with iodoethane and K2CO3 to afford (IV). Finally, displacement of the 2-chloro of (IV) with cis-1,2-cyclohexanediamine (V) at 150 C furnished the title compound.
【1】 Imbach, P.; Capraro, H.G.; Furet, P.; Mett, H.; Meyer, T.; Zimmermann, J.; 2,6,9-Trisubstituted purines: Optimization towards highly potent and selective CDK1 inhibitors. Bioorg Med Chem Lett 1999, 9, 1, 91. |
【2】 Capraro, H.-G.; Zimmermann, J.; Furet, P.; Peterli, P. (Novartis AG); Purine derivs. and processes for their preparation. JP 1999514336; WO 9716452 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 25254 | 2,6-dichloro-9H-purine | 5451-40-1 | C5H2Cl2N4 | 详情 | 详情 |
(II) | 25239 | 3-chloroaniline; 3-chlorophenylamine | 108-42-9 | C6H6ClN | 详情 | 详情 |
(III) | 59602 | 2-chloro-N-(3-chlorophenyl)-9H-purin-6-amine; N-(3-chlorophenyl)-N-(2-chloro-9H-purin-6-yl)amine | C11H7Cl2N5 | 详情 | 详情 | |
(IV) | 59603 | 2-chloro-N-(3-chlorophenyl)-9-ethyl-9H-purin-6-amine; N-(2-chloro-9-ethyl-9H-purin-6-yl)-N-(3-chlorophenyl)amine | C13H11Cl2N5 | 详情 | 详情 | |
(V) | 37409 | (1R,2S)-2-aminocyclohexylamine; (1R,2S)-1,2-cyclohexanediamine | 1121-22-8 | C6H14N2 | 详情 | 详情 |
Extended Information